PURPOSE: The present study analyzed the polymorphisms of DNA repair genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. PATIENTS AND METHODS: A total of 94 patients with recurrent or metastatic colorectal cancer treated with oxaliplatin-based combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 16 DNA repair genes were determined using a PCR-RFLP assay. RESULTS: During the median follow-up duration of 15.9 (2.1-53.0) months, 67 (71.3%) progressions and 29 (30.9%) deaths were observed. Among the 60 patients assessable for response, response to the oxaliplatin-based regimens was found in 27 (45%) patients (9 CR and 18 PR). In a logistic regression analysis adjusted to age, sex, primary site, disease status, and regimen, the POLR2C rs4937 and MSH2 rs3732183 polymorphisms were statistically associated with the response to the oxaliplatin-based chemotherapy. A multivariate survival analysis showed that the TT genotype of the MGMT (rs1625649) -535G>T polymorphism was found to correlate with a worse progression-free survival (PFS) than the combined GG + GT genotypes (HR = 3.137; 95% CI = 1.423-6.914; P = 0.005), which was also observed among the 60 evaluable patients (HR = 2.653; 95% CI = 1.101-6.392; P = 0.030) For the clinical parameters, curative resection was the most significant prognostic factor in a Cox model for PFS and overall survival (HR = 0.229 and 0.205; P < 0.001 and 0.001, respectively). CONCLUSION: The MGMT -535G>T polymorphism (rs1625649) was found to be correlated with PFS in patients with advanced colorectal cancer treated with oxaliplatin-based chemotherapy.
PURPOSE: The present study analyzed the polymorphisms of DNA repair genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. PATIENTS AND METHODS: A total of 94 patients with recurrent or metastatic colorectal cancer treated with oxaliplatin-based combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 16 DNA repair genes were determined using a PCR-RFLP assay. RESULTS: During the median follow-up duration of 15.9 (2.1-53.0) months, 67 (71.3%) progressions and 29 (30.9%) deaths were observed. Among the 60 patients assessable for response, response to the oxaliplatin-based regimens was found in 27 (45%) patients (9 CR and 18 PR). In a logistic regression analysis adjusted to age, sex, primary site, disease status, and regimen, the POLR2Crs4937 and MSH2rs3732183 polymorphisms were statistically associated with the response to the oxaliplatin-based chemotherapy. A multivariate survival analysis showed that the TT genotype of the MGMT (rs1625649) -535G>T polymorphism was found to correlate with a worse progression-free survival (PFS) than the combined GG + GT genotypes (HR = 3.137; 95% CI = 1.423-6.914; P = 0.005), which was also observed among the 60 evaluable patients (HR = 2.653; 95% CI = 1.101-6.392; P = 0.030) For the clinical parameters, curative resection was the most significant prognostic factor in a Cox model for PFS and overall survival (HR = 0.229 and 0.205; P < 0.001 and 0.001, respectively). CONCLUSION: The MGMT -535G>T polymorphism (rs1625649) was found to be correlated with PFS in patients with advanced colorectal cancer treated with oxaliplatin-based chemotherapy.
Authors: Thibaud Koessler; Elizabeth M Azzato; Barbara Perkins; Robert J Macinnis; David Greenberg; Douglas F Easton; Paul D P Pharoah Journal: Int J Cancer Date: 2009-04-15 Impact factor: 7.396
Authors: S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Joon Ho Moon; Jong Gwang Kim; Sang Kyun Sohn; Jin Ho Baek; Yoon Young Cho; Yee Soo Chae; Byung Min Ahn; Shi Nae Kim; Soo Jung Lee; In Taek Lee; Gyu Seog Choi; Soo Han Jun Journal: J Korean Med Sci Date: 2007-06 Impact factor: 2.153
Authors: S Ma; S Egyházi; T Ueno; C Lindholm; E L Kreklau; U Stierner; U Ringborg; J Hansson Journal: Br J Cancer Date: 2003-10-20 Impact factor: 7.640
Authors: Emma C Hulshof; Lifani Lim; Ignace H J T de Hingh; Hans Gelderblom; Henk-Jan Guchelaar; Maarten J Deenen Journal: Front Pharmacol Date: 2020-10-06 Impact factor: 5.810
Authors: Meixiang Xu; Ilona Nekhayeva; Courtney E Cross; Catherine M Rondelli; Jeffrey K Wickliffe; Sherif Z Abdel-Rahman Journal: Carcinogenesis Date: 2013-10-25 Impact factor: 4.944
Authors: Jaime Antonio Oliver; Raúl Ortiz; Consolación Melguizo; Pablo Juan Alvarez; Jaime Gómez-Millán; Jose Prados Journal: BMC Cancer Date: 2014-07-11 Impact factor: 4.430